Factors associated with the success of rabies vaccination of dogs in Sweden by Berndtsson, Louise T et al.
RESEARCH Open Access
Factors associated with the success of rabies
vaccination of dogs in Sweden
Louise T Berndtsson
*†, Ann-Kristin J Nyman
†, Esteban Rivera, Berndt Klingeborn
†
Abstract
Background: United Kingdom, Ireland, Malta and Sweden maintain their national provisions for a transitional
period regarding rules concerning rabies vaccination and individual serological test for rabies neutralizing
antibodies. The purpose of vaccinating dogs against rabies is to establish pre-exposure immunity and protect
individual animals from contracting rabies.
The aim of the study was to investigate factors associated with reaching the internationally accepted threshold
antibody titre of 0.5 IU/mL after rabies vaccination of dogs.
Methods: The study was a prospective single cohort study including 6,789 samples from Swedish dogs vaccinated
with commercially available vaccines in Sweden, and the dog’s antibody responses were determined by the OIE
approved FAVN test. Information on potential risk factors; breed, age, gender, date of vaccination, vaccine label and
the number of vaccinations, was collected for each dog. Associations between the dependent variable, serological
response ≥ 0.5 IU/mL or < 0.5 IU/mL and each of the potential risk factors were investigated using logistic
regression analysis.
Results: Of 6,789 vaccinated dogs, 6,241 (91.9%) had an approved test result of ≥ 0.5 IU/mL. The results of the
multivariable logistic regression analysis showed that vaccinating with vaccine B reduced the risk of having
antibody titres of < 0.5 IU/mL by 0.2 times compared with vaccination using vaccine A. Breed size was found
significant as an interaction with number of vaccinations and age at vaccination as an interaction with day of
antibody testing after last vaccination. In summary, larger breeds were at higher risk of having antibody titres of
< 0.5 IU/mL but if vaccinated twice this risk was reduced. Moreover, there were a increased risk for dogs
< 6 months of age and > 5 years of age to have antibody titres of < 0.5 IU/mL, but this was affected by number
of days from vaccination till testing.
Conclusions: The probability of success of rabies vaccinations of dogs depends on type of vaccine used, number of
rabies vaccinations, the breed size of the dog, age at vaccination, and number of days after vaccination when the
antibody titres are tested. The need for a booster vaccination regimen is recommended for larger breeds of dog.
Background
Sweden is free from rabies since more than 100 years.
When Sweden joined the European Union 1994 the
obligatory quarantine system was abandoned and new
rules for non-commercial movement of pet animals
(dogs, cats and ferrets) were put in place. The rules are
laid down in Directive 998/2003 of the European Com-
munity [1]. According to these rules all animals should
be identified by tattoo and/or microchip and vaccinated
against rabies, and a 21-day waiting period in case
of primary vaccination. In addition, article 6 of the
above Regulation provides that four countries, United
Kingdom, Ireland, Malta and Sweden, maintain their
national provisions for a transitional period. For Sweden
these derogations consist of the requirement of an indi-
vidual serological test for rabies neutralizing antibodies
before entry into Sweden earliest 120 days after the
latest vaccination.
The purpose of vaccinating cats and dogs against
rabies is to establish pre-exposure immunity and protect
individual animals from contracting rabies, hereby pre-
venting further spread to humans or other domestic
animals.
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number of vaccinations, interval between vaccination
and blood sampling, age at vaccination, size and breed
c a ni n f l u e n c et h ea n t i b o d yr e s p o n s e[ 2 - 5 ] ,b u tt h i sh a s
not been investigated in Sweden.
The aim of the study was to investigate factors asso-
ciated with reaching the internationally accepted thresh-
old antibody titre of 0.5 IU/mL after rabies vaccination
of dogs.
Methods
Study design
The study was a prospective single cohort study includ-
ing 6,789 blood samples from dogs received by the
National Veterinary Institute (SVA) during 2005 for the
analysis of the serological response to rabies vaccination.
The samples were either whole blood samples or sera
from dogs vaccinated with one of the two commercially
available vaccines in Sweden. To qualify into the study
the dogs had to be vaccinated in Sweden and been vac-
cinated against rabies with one of the two in Sweden
commercially available vaccines, and samples for serolo-
gical analyses had to be sent in to SVA.
The samples were collected as routine samples, hence,
not especially for this study. Owners were informed at
sampling that the sample could be used for research
and they were given the opportunity to not let the sam-
ple be used for research.
Vaccines
Two, in Sweden commercially available monovalent inac-
tivated rabies vaccines, were evaluated. A: Nobivac
®
Rabies Vet. (Intervet AB) and B: Rabisin
® Vet. (Merial
Norden A/S). From here on these vaccines are referred
to as vaccines A and B, respectively. Vaccine A contains
≥ 2 IU of the rabies virus strain RIV (Pasteur Institute)
per vaccine dose plus aluminum phosphate as adjuvant
and vaccine B contains ≥ 1 IU of rabies virus Wistar G
57 (Pasteur Institute) and aluminum hydroxide as adju-
vant. The main task of adjuvants is to induce an inflam-
matory response which is needed for an adaptive
immune response including T and B cells. Also adjuvant
can be important for constituting depot effect enabling a
sustained presence of the vaccine antigen in the body,
Adjuvants can also be important for the need of less vac-
cine antigen in an adjuvanted vaccine. The dogs were
immunized following the vaccine producers’ instructions.
Sample collection
Blood samples were collected throughout the country at
different veterinary clinics. The samples were collected
120 days post vaccination up to 360 days post vaccina-
tion. The samples from the dogs included in this study
were accompanied by referrals containing breed, age,
gender, date of vaccination, vaccine label and the
number of vaccinations. Of the 6,789 dogs included
in the study 3,571 (52.6%) received vaccine A and
3,218 (47.4%) dogs received vaccine B.
Serological analysis
All the samples were analyzed at the SVA. The antibody
responses were determined by the OIE approved FAVN
test [6]. Dogs with titres of ≥ 0.5 IU/mL were consid-
ered to have passed the test and dogs with titres of
< 0.5 IU/mL were considered to have failed the test. An
antibody titre of ≥ 0.5 IU/mL is the international
accepted threshold after rabies vaccination of dogs.
Statistical analysis
Associations between the dependent variable, serologi-
cal response ≥ 0.5 IU/mL or < 0.5 IU/mL and each of
the potential risk factors; type of vaccine, day of sam-
pling after last vaccination, number of vaccinations,
age at vaccination, breed size, pure-bred or not, and
gender were first investigated using univariable logistic
regression analysis. Before the regression analysis the
linear association between age at vaccination and the
dependent variable was investigated on a logistic scale,
and was found not linear, hence, age at vaccination
was categorized into 5 approximately evenly sized cate-
gories. Pure-bred dogs were categorized according to
size, using information on the website http://www.
svenskhund.se/hund_raspresentation.asp?val=lista&
sort=storlek (in Swedish) where breed sizes, based on
the definitions in the breeding standards, are categor-
ized into four categories; very small - small (< 30 cm
in height), small - medium (30-45 cm in height), med-
ium - large (45-60 cm in height), and large - very large
(> 60 cm in height). There was no information about
t h eh e i g h to fd o g so fm i x e db r e e ds ot h e yw e r ec a t e -
gorized as dogs of unknown size (only including mixed
breeds) in the breed size variable. All variables, pro-
vided that there was no collinearity (r < 0.70) between
variables, were then considered for the multivariable
analysis. Collinearity between variables was assessed
pair-wise by calculation of Spearman rank correlations.
A multivariable model was constructed using manual
stepwise backwards regression analysis, where variables
not significant in the model were re-entered whenever
a new variable became significant, or a variable was
removed. Potential confounders were considered, and a
variable was considered as a confounder if the point
estimates of the coefficients in a model change > 20%
with the potential confounder present. In the final
model a variable with a P-value ≤ 0.05 was considered
statistically significant and retained in the model. Bio-
logically plausible interactions between the main
effects were tested in the final model.
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and Lemeshow [7]. The fit of the model was evaluated
with the Hosmer-Lemeshow goodness-of-fit test with
the data partitioned into 10 deciles, and by visual exami-
nation of diagnostic plots. Plot of Pearson residuals (r),
leverage (h) ,d e l t ab e t a( Δb), delta deviance (ΔD), and
delta chi
2 (Δc
2) versus the predicted values were con-
structed and evaluated. Observations with divergent
values, i.e. -3 ≤ r ≥ 3, h >0 . 3 ,Δb >1 ,ΔD>4 . 0 ,o rΔc
2
> 4.0 were considered outliers. The impact of outliers
was assessed by running the model without the observa-
tions considered as outliers, and comparing the coeffi-
cients between this model and the model using all
observations. Data editing and all the statistical analyses
were performed in Stata Software (StataCorp., 2003;
Stata Statistical Software: Release 10.0; College Station,
TX, USA: StataCorp LP.).
Results
Descriptive data and univariable analysis
Descriptive data of the dependent variable and the risk
factors investigated, and their P-value in the univariable
analysis are presented in Table 1. Of 6,789 vaccinated
dogs, 6,241 (91.9%) had an approved test result of ≥ 0.5
IU/mL. There were 3,571 dogs vaccinated using vaccine
A, and 3,218 dogs vaccinated using vaccine B. In the
univariable analysis it was shown that dogs vaccinated
with vaccine B more often reached approved antibody
titres than dogs vaccinated with vaccine A (P < 0.001).
Moreover, significantly more dogs reached approved test
results if antibody titres were checked at day 120-150
after vaccination compared to if they were checked at
day 151-180 (P < 0.004), and two immunizations signifi-
cantly increased the number of dogs reaching approved
test results (P < 0.001). Dogs < 6 month and ≥ 5 years
more often had less success in reaching approved test
result compared with dogs between 6 months < 5 years
of age (P < 0.05). Breed size and breed was also signifi-
cantly associated with approved test result in the uni-
variable analysis; smaller dogs and dogs of mixed breed
were more likely to reach approved test results com-
pared with larger dogs and pure-bred dogs (P < 0.05).
Multivariable analysis
Of all the 6 variables considered in the multivariable
analysis only gender was not retained in the final model.
In the final model only type of vaccine remained as a
main effect while breed size was found significant as an
interaction with number of vaccinations and age at vac-
cination as an interaction with day of antibody testing
after last vaccination (Table 2 and Figure 1). The results
show that vaccinating with vaccine B will reduce the
Table 1 Distribution of potential risk factors associated with the success (antibody titres ≥ 0.5 IU/ml) of rabies
vaccination in dogs (n = 6,789)
Variable Level Number of
animals
Proportion of dogs with
antibody titres ≥ 0.5 IU/ml, %
P-value in the univariable
logistic regression analysis
Type of vaccine 1:Vaccine A 3571 87.4
2:Vaccine B 3218 96.9 <0.001
Day of antibody testing
after last vaccination
1: 120 - 150 days 5156 92.6
2: 151 - 180 days 1613 90.3 0.003
Number of vaccinations 1: Once 1766 85.7
2: Twice 5023 94.1 < 0.001
Age at vaccination 1: < 6 month 1635 89.5
2: 6-11.9 months 1050 92.6
3: 1-2.49 years 1692 93.8
4: 2.5 - 4.99 years 1053 92.6
5: ≥ 5 years 698 90.4 < 0.001
Breed size 1: Very small/small pure-breed
(< 30 cm in height)
1482 94.1
2: Small/medium sized pure-
breed (30-45 cm in height)
1203 92.2
3: Medium/large pure-breed
(46-60 cm in height)
1965 91.4
4: Large/very large pure-breed
(> 60 cm in height)
1345 88.4
5: Unknown size mixed breeds 747 94.5 < 0.001
Gender 1: Bitch 3637 91.4
2: Dog 3152 92.5 0.12
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Page 3 of 7risk of having antibody titres of < 0.5 IU/mL by 0.2
times (i.e. if 10% of the dogs vaccinated with vaccine A
fail to reach an antibody titre of ≥ 0.5 IU/mL, only 2%
of the dogs would have failed if vaccinated with vaccine
B instead).
Medium to large and large to very large pure-bred
dogs were at increased risk of having antibody titres of
< 0.5 IU/mL compared to very small to small pure-bred
dogs or mixed breed dogs of unknown size when vacci-
nated once. However, if medium to large and large to
very large pure-bred dogs were vaccinated twice com-
pared to once, the risk of having antibody titres of < 0.5
IU/mL were reduced. For pure-bred dogs of small to
medium size and for dogs of mixed breed of unknown
size there was no significant difference in risk of having
antibody titers < 0.5 IU/mL. Of dogs vaccinated twice
there were an increased risk for small to medium and
large to very large pure-bred dogs to have antibody
titres of < 0.5 IU/mL vaccinated compared to very small
to small pure-bred dogs and mixed breed dogs of
unknown size.
Dogs at an age ≥ 6 months at vaccination had a
decreased risk of having antibody titres < 0.5 IU/mL
than dogs < 6 month of age at vaccination when anti-
body levels were tested at day 120-151 after last vaccina-
tion. There was no difference in risk between dogs ≥ 6
months tested at day 120-151. For dogs ≥ 5 years there
were an increased risk of having antibody titres < 0.5
IU/mL if the antibody level was tested at day 151-180
compared with if the antibody level was tested at day
120-150 after last vaccination. For dogs < 5 years there
was no difference in risk if the antibody level were
tested at day 120-150 or 151-180 days after vaccination.
Dogs at the age of 1-2.49 years at vaccination that were
tested for antibody levels at day 151-180 had a reduced
risk of having antibody titres < 0.5 IU/mL compared to
dogs < 6 months, and dogs of ≥ 5 years of age at the
time of vaccination, that were tested at day 151-180.
Table 2 Final multivariable logistic regression analysis of variables significantly (P ≤ 0.05) associated with success of
rabies vaccinations in 6,071 Swedish dogs (pseudo R
2 = 0.11)
Variable b S.E.(b)O R
a 95% CI
b (OR
a) P-value
Intercept -1.44 0.19 - - -
Vaccine
A: Nobivac Ref - - - -
B: Rabisin -1.47 0.12 0.23 0.18, 0.29 < 0.001
Interactions
Breed size * no of vaccinations
Very small -small breed size * vaccinated once Ref - - - -
Small - medium bred size * vaccinated once 0.07 0.27 1.07 0.63, 1.84 0.79
Medium - large breed size * vaccinated once 0.68 0.21 1.97 1.29, 3.00 0.002
Large - very large breed size * vaccinated once 0.81 0.22 2.25 1.45, 3.49 < 0.001
Unknown size (mixed breed) * vaccinated once -0.41 0.38 0.66 0.32, 1.39 0.28
Very small -small breed size * vaccinated twice -0.90 0.24 0.41 0.25, 0.65 < 0.001
Small - medium bred size * vaccinated twice -0.31 0.22 0.73 0.47, 1.13 0.16
Medium - large breed size * vaccinated twice -0.61 0.21 0.54 0.36, 0.82 0.004
Large - very large breed size * vaccinated twice -0.07 0.21 0.93 0.62, 1.42 0.75
Unknown size (mixed breed) * vaccinated twice -0.91 0.29 0.40 0.23, 0.72 0.002
Age at vaccination * number of day after vaccination a.b. titres were tested
< 6 month * day 120-150 Ref - - - -
6-11.9 month * day 120-150 -0.40 0.17 0.67 0.48, 0.93 0.018
1-2.49 years * day 120-150 -0.67 0.16 0.51 0.38, 0.70 < 0.001
2.5-4.99 years * day 120-150 -0.63 0.18 0.53 0.38, 0.75 < 0.001
≥ 5 years *day 120-150 -0.41 0.19 0.66 0.45, 0.96 0.032
< 6 month * day 151-180 -0.10 0.20 0.90 0.60, 1.35 0.62
6-11.9 month * day 151-180 -0.24 0.25 0.78 0.48, 1.29 0.34
1-2.49 years * day 151-180 -0.63 0.22 0.53 0.34, 0.82 0.004
≥ 2.56 years * day 151-180 -0.12 0.24 0.89 0.56, 1.42 0.62
≥ 5 years *day 151-180 0.58 0.25 1.80 1.10, 2.93 0.019
aOR = odds ratio.
bCI = confidence interval.
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Page 4 of 70 .1 .2 .3 .4 .5
Pr(test result <0.5 IU/mL)
Vaccine B
Vaccine A
Type of vaccine A.
0 .1 .2 .3 .4 .5
Pr(test result <0.5 IU/mL)
mb*twice
l-vl*twice
m-l*twice
s-m*twice
vs-s*twice
mb*once
l-vl*once
m-l*once
s-m*once
vs-s*once
Breed size and number of vaccinations B.
0 .1 .2 .3 .4 .5
Pr(test result <0.5 IU/mL)
>=5y*151-180
2.5-4.9y*151-180
1-2.49y*151-180
6-11.9m*151-180
<6m*151-180
<=5y*120-150
2.5-4.9y*120-150
1-2.49y*120-150
6-11.9m*120-150
<6m*120-150
Age at vaccination and day of anitbody titre testing C.
Figure 1 Distribution of the probability of having antibody levels of < 0.5 IU/ml for all main effects and interactions. A. Type of vaccine
used. B. Interaction between breed size
1 and number of vaccinations. C. Interaction between age
2 at vaccination and time of antibody titre
testing after the latest vaccination in the final multivariable logistic regressions analysis of variables associated with the success of rabies
vaccinations in 6,071 Swedish dogs.
1vs-s = very small - small breed; s-m = small - medium breed; m-l = medium - large breed; l-vl = large to
very large breed.
2Age in month (m) or year (y).
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of other ages tested at day 151-180.
Model fit
The final model showed good fit; the Hosmer-Leme-
show c
2 (8 d.f.) was 6.42 (P = 0.60). When looking at
different plots of r, h, Δb, ΔDa n dΔ c
2, several diver-
gent covariates were seen (n = 2-8, dependent on which
diagnostic value was addressed), but the coefficients did
not change considerably and the model did not improve
much with deletion of the divergent observations.
Discussion
This study comprised 6,789 blood samples from dogs
analyzed for the serological response to rabies vaccina-
tion. An important outcome of the study was the signifi-
cant difference in failure rates between the two vaccines
used in Sweden. This has also been shown by others
[2,5,8]. However, the study includes a large number of
dogs, which were all tested more than 120 days post
vaccination. The majority of dogs were also vaccinated
twice, and to the best of our knowledge there is no
comparative published data on the use of two doses of
rabies vaccine and samples taken after more than
120 days.
This study confirms the finding of Minke et al. [4]
that there were significant differences in immunogeni-
city between the vaccines A and B in an experimental
vaccination trial in laboratory dogs. Two vaccinations
increased the numbers of dogs reaching approved test
results in the present study (Table 1, Figure 1). How-
ever, the difference in performance between the two
vaccines did not change with two vaccinations compared
to one (there were no significant interaction between
number of vaccinations and type of vaccine). The differ-
ence between the two vaccines can be caused by a true
varying immunogenicity of the vaccines due to the virus
strains, adjuvant used or the test system. The prescribed
standardized FAVN test is using the CVS rabies virus
strain as test virus and it was shown that use of homo-
logous virus strains resulted in higher antibody titres
in comparison to heterologous virus present in the
vaccines [9].
Dogs vaccinated at an age less than 6 months or over
5 years of age had a higher failure rate than dogs
between 6 months and 5 years. This is in concordance
with findings of Mansfield et al. [2] and Kennedy et al.
[3] that both showed a higher risk of lower antibody
titres with increasing age as well as for dogs less than
one year of age compared to adults. The higher risk of
lower antibody titres in older dogs could be due to a
reduced efficiency of the immune system with increasing
age, however this reduced efficiency may not influence
the antibody response [10,11]. The explanation for
higher risk of lower antibody titres in younger dogs
could be due to that the vaccine has been administered
before the dog has reached immunocompetence [12].
In the present study significantly more dogs sampled
at day 120-150 post vaccination reached approved test
results than dogs sampled at day 151-180 (Tables 1, 2;
Figure 1). An increasing proportion of dogs failing to
reach the antibody response cut-off with increasing days
from vaccination to sampling were also shown by Ken-
n e d ye ta l .[ 3 ] .M o r e o v e r ,J a k e le ta l .[ 5 ]s h o w e dt h a t
dogs sampled up to 4 month after vaccination had a sig-
nificantly higher chance of reach the antibody response
cut-off than dogs sampled at later time-points indepen-
dently if the dogs had been vaccinated once or twice.
However, Kennedy et al. [3] arguments that this lower
response may not relate to a lack of immune protection
as the total immunoglobulin measure may be proportio-
nately more accounted for by IgG as dog’s iso-type shifts
from an IgM response to an IgG as an immune
response develops.
Medium-large and large-very large pure-bred dogs had
less success reaching approved test results compared to
very small-small pure-bred dogs vaccinated once. This
difference was reduced when the dogs were vaccinated
t w i c e( F i g u r e1 B ) .K e n n e d ye ta l .[ 3 ]s h o w e dt h a tm o s t
failures were in larger breeds, but also some smaller
breeds had important failure rates. Jakel et al. [5] could
not find any differences in antibody response between
breeds. We chose breed size as a factor and not specific
pure breeds as such, and the high proportion of mixed
breed dogs successfully reachi n ga n t i b o d yr e s p o n s ec u t -
off (Table 1) could be speculated to be either an effect of
crossbreeding or that they might be of a small size, or a
combination of both. It is well known that genetic varia-
tions across breeds are large, whereas within breed varia-
tion is much more limited. However, sampling cases
from only one geographic location, i.e. Sweden, can cause
false results for a particular breed due to a significant
intra-breed genetic diversity between countries [13].
In concordance with Mansfield et al [2] and Jakel
et al. [5] we could not find any differences in antibody
response due to gender.
Based upon the results of the present study and the
studies previously performed by others we would like to
make the recommendations to vaccinate twice if the dog
is of a larger breed.
Conclusions
The probability of success of rabies vaccinations of dogs
depends on type of vaccine used, number of rabies vac-
cinations, the breed size of the dog, age at vaccination,
and number of days after vaccination when the antibody
titres are tested. The need for a booster vaccination
regimen is recommended for larger breeds of dog.
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